title: Genetic susceptibility in solvent induced neurobehavioral effects.
abstract: The aim of this investigation was to study the influence of genetic polymorphisms of biotransformation enzymes and dopamine receptors on neurobehavioral effects in referents (n = 53), solvent-workers (n = 144), and chronic toxic encephalopathy (CTE) patients (n = 33). All participants were interviewed for exposure data and confounding factors and underwent a clinical examination. Neurobehavioral complaints (neurotoxicity symptom checklist-60) and effects [simple reaction time (SRT), symbol digit substitution (SDS), hand-eye coordination (HEC), and digit span backwards (DSB)] were evaluated with a computer assisted test battery. The following genotypes were determined: GSTM1, GSTT1, GSTP1, DRD2 Taq1A, DRD2 Taq1B, and DRD2-141Cdel. Neurotoxic effects and complaints were significantly higher in CTE patients and were related to both duration and level of exposure. An equal distribution of genotypes was found between all groups. Logistic regression analysis revealed that GSTT1 was negatively associated with sleep and sensorimotor complaints. GSTM1 had a protecting influence on the relationship between logDSB and the cumulative exposure index and between logSRT and cumulative exposure index and degree of exposure, respectively. This effect was also found when correcting for age, education level, alcohol consumption, and smoking. DRD2-141Cdel polymorphisms had a negative influence on the relationship between logSDS and the total exposure time. GSTT1 might be protective against sleep and sensorimotor complaints, whereas GSTM1 seems to decrease sustained attention and short-term memory problems in relation to solvent exposure. Individuals possessing DRD2-141Cdel variant experienced more visuomotor problems.
authors.affiliation: Department of Occupational, Environmental and Insurance Medicine, Katholieke Universiteit Leuven, Kapucijnenvoer 35/5, Leuven, 3000, Belgium. lode.godderis@med.kuleuven.be
authors.forename: L
authors.initials: L
authors.lastname: Godderis
authors.forename: N
authors.initials: N
authors.lastname: Maertens
authors.forename: V
authors.initials: V
authors.lastname: de Gelder
authors.forename: A
authors.initials: A
authors.lastname: De Lamper
authors.forename: K
authors.initials: K
authors.lastname: De Ruyck
authors.forename: M
authors.initials: M
authors.lastname: Vernimmen
authors.forename: S
authors.initials: S
authors.lastname: Bulterys
authors.forename: G
authors.initials: G
authors.lastname: Moens
authors.forename: H
authors.initials: H
authors.lastname: Thierens
authors.forename: M K
authors.initials: MK
authors.lastname: Viaene
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D003936:Diagnosis, Computer-Assisted; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008433:Mathematics; D008875:Middle Aged; D009460:Neurologic Examination / Q000379:methods; D009483:Neuropsychological Tests; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000235:genetics*; D016273:Occupational Exposure; D011110:Polymorphism, Genetic / Q000235:genetics*; D011930:Reaction Time / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012907:Smoking; D012997:Solvents / Q000633:toxicity*; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires
chemical_list: D017448:Receptors, Dopamine D2; D012997:Solvents; C413545:glutathione S-transferase T1; D005982:Glutathione Transferase
references.citation: Anal Biochem. 1996 Apr 5;236(1):184-6
references.pmid: 8619490
references.citation: Scand J Work Environ Health. 1996 Oct;22(5):360-3
references.pmid: 8923609
references.citation: Occup Environ Med. 2006 Mar;63(3):221-6, 179
references.pmid: 16497867
references.citation: IARC Sci Publ. 1997;(142):251-64
references.pmid: 9354924
references.citation: QJM. 2002 Jun;95(6):379-87
references.pmid: 12037246
references.citation: Occup Environ Med. 2007 Oct;64(10):673-80
references.pmid: 17449559
references.citation: Mov Disord. 2003 May;18(5):593-5
references.pmid: 12722176
references.citation: J Neurol. 1999 Mar;246(3):198-206
references.pmid: 10323318
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1038-42
references.pmid: 16702390
references.citation: Scand J Work Environ Health. 1990;16 Suppl 1:17-25
references.pmid: 2189216
references.citation: Neurotoxicology. 2000 Oct;21(5):659-65
references.pmid: 11130269
references.citation: Eur J Nucl Med. 1999 Feb;26(2):171-82
references.pmid: 9933352
references.citation: Int J Hyg Environ Health. 2006 Mar;209(2):139-50
references.pmid: 16503300
references.citation: Pharmacogenomics. 2000 Aug;1(3):309-33
references.pmid: 11256581
references.citation: Neurotoxicology. 1999 Feb;20(1):7-16
references.pmid: 10091854
references.citation: Int Arch Occup Environ Health. 1997;70(3):180-6
references.pmid: 9298400
references.citation: Environ Mol Mutagen. 2004;44(4):293-303
references.pmid: 15468052
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20552-7
references.pmid: 18077373
references.citation: Neurotox Res. 2007 Jan;11(1):61-72
references.pmid: 17449449
references.citation: Eur Psychiatry. 2002 Mar;17(1):17-23
references.pmid: 11918988
references.citation: Ann N Y Acad Sci. 2008;1129:200-12
references.pmid: 18591481
references.citation: Lancet. 1997 Apr 26;349(9060):1239-43
references.pmid: 9130958
references.citation: Environ Health Perspect. 1991 Jan;90:195-8
references.pmid: 2050061
references.citation: Ind Health. 1994;32(3):145-64
references.pmid: 7698903
references.citation: Neurosci Behav Physiol. 2003 Mar;33(3):223-5
references.pmid: 12762588
references.citation: Neurotoxicology. 2003 Aug;24(4-5):491-501
references.pmid: 12900062
references.citation: Toxicol Ind Health. 2002 Jul;18(6):289-96
references.pmid: 14992466
references.citation: Pharmacogenetics. 2000 Dec;10(9):781-8
references.pmid: 11191882
references.citation: Toxicol Ind Health. 2006 Aug;22(7):281-9
references.pmid: 17022435
references.citation: Ann Neurol. 2008 May;63(5):572-80
references.pmid: 18412121
references.citation: Pharmacogenetics. 2002 Dec;12(9):691-702
references.pmid: 12464798
references.citation: Neuroscience. 2009 Nov 24;164(1):131-40
references.pmid: 19393722
references.citation: Toxicology. 2003 Apr 15;186(1-2):131-41
references.pmid: 12604177
references.citation: Mol Psychiatry. 2007 May;12(5):454-61
references.pmid: 17453061
references.citation: Neuropsychopharmacology. 2006 Jan;31(1):231-42
references.pmid: 16123753
references.citation: Hum Mol Genet. 1997 Apr;6(4):577-82
references.pmid: 9097961
references.citation: Toxicology. 2006 Feb 15;219(1-3):220-9
references.pmid: 16386346
references.citation: Occup Environ Med. 2001 Feb;58(2):103-12
references.pmid: 11160988